Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 19, 2008

Kyowa Hakko Gains Asian Rights to Alnylam’s RSV Therapeutic in $93M Deal

  • Alnylam Pharmaceuticals and Kyowa Hakko Kogyo forged an exclusive alliance to develop and commercialize ALN-RSV01 in Japan and other major markets in Asia. ALN-RSV01 is Alnylam’s lead RNAi therapeutic, which is in Phase II development for the treatment of respiratory syncytial virus infection.

    Kyowa Hakko will pay Alnylam $15 million upfront and up to an additional $78 million in development and sales milestone payments. Upon commercialization, Alnylam will receive double-digit royalties from Kyowa Hakko based on the sales of ALN-RSV01 in this territory. The partnership also includes additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program. Alnylam retains all development and commercialization rights worldwide, excluding Asia.

    Related Links:

    RNAi Researchers Galvanized by Advances

    RNAi Technologies Become Discovery Staple

    Multidisciplinary Approach to RNAi

  • You’re all set! Thank you for subscribing to GEN Highlights.